Consistent with what has been reported in previous studies, in this research, we found that the expression of MIAT was enhanced in breast cancer tissues and cells and that highly expressed MIAT was associated with multiple clinical characteristics of patients, including age, tumor size, low grade, ER status, HER2 status, P53 status, and tumor stage. Here, ERBB2 is linked to neoplasm.